Clinical Trial Update: Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years) [Phase 1]

View source ↗

Summary

Phase 1 study in healthy adults (19-49) evaluating safety and immunogenicity of a pneumococcal conjugate vaccine candidate developed by Sanofi Pasteur.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Pneumococcal conjugate vaccine candidate

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Pneumococcal Immunization | Phase 1 | Status: COMPLETED